Potential therapeutic applications of thyroid hormone analogs

Thyroid hormone (T3 and T4) has many beneficial effects including enhancing cardiac function, promoting weight loss and reducing serum cholesterol. Excess thyroid hormone is, however, associated with unwanted effects on the heart, bone and skeletal muscle. We therefore need analogs that harness the beneficial effects of thyroid hormone without the untoward effects. Such work is largely based on understanding the cellular mechanisms of thyroid hormone action, specifically the crystal structure of the nuclear receptor proteins. In clinical studies, use of naturally occurring thyroid hormone analogs can suppress TSH levels in patients with thyroid cancer without producing tachycardia. Many thyromimetic compounds have been tested in animal models and shown to increase total body oxygen consumption, and to lower weight and serum cholesterol and triglyceride levels while having minor effects on heart rate. Alternatively, analogs that specifically enhance both systolic and diastolic function are potentially useful in the treatment of chronic congestive heart failure. In addition to analogs that are thyroid hormone receptor agonists, several compounds that are thyroid hormone receptor antagonists have been identified and tested. This Review discusses the potential application of thyroid hormone analogs (both agonists and antagonists) in a variety of human disease states.

[1]  F. B. Davis,et al.  Nongenomic actions of thyroid hormone on the heart. , 2002, Thyroid : official journal of the American Thyroid Association.

[2]  G. Kahaly,et al.  Thyroid hormone action in the heart. , 2005, Endocrine reviews.

[3]  M. Suzuki.  Thyroid Hormone Receptor , 2020, Definitions.

[4]  F. M. Nunes,et al.  Crystallization and preliminary X‐ray diffraction studies of isoform α1 of the human thyroid hormone receptor ligand‐binding domain , 2004 .

[5]  R. Fletterick,et al.  Definition of the Surface in the Thyroid Hormone Receptor Ligand Binding Domain for Association as Homodimers and Heterodimers with Retinoid X Receptor* , 2001, The Journal of Biological Chemistry.

[6]  R. Koenig.  Regulation of type 1 iodothyronine deiodinase in health and disease. , 2005, Thyroid : official journal of the American Thyroid Association.

[7]  B. Gloss,et al.  The Thyroid Hormone Receptor-β-Selective Agonist GC-1 Differentially Affects Plasma Lipids and Cardiac Activity. , 2000, Endocrinology.

[8]  J. Harney,et al.  Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. , 2005, The Journal of clinical investigation.

[9]  Thomas S. Scanlan,et al.  Rapid nongenomic actions of thyroid hormone , 2006, Proceedings of the National Academy of Sciences.

[10]  J. Baxter,et al.  Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  S. Thomas,et al.  Thyroid hormone treatment after coronary-artery bypass surgery. , 1995, The New England journal of medicine.

[12]  B Gerbert,et al.  [Thyroid hormone and the cardiovascular system]. , 2005, Deutsche medizinische Wochenschrift.

[13]  Johan Malm,et al.  Selective thyroid hormone receptor-β activation: A strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  H. Thai,et al.  Thyroid Hormone Analog, DITPA, Improves Endothelial Nitric Oxide and Beta-Adrenergic Mediated Vasorelaxation after Myocardial Infarction , 2004, Journal of cardiovascular pharmacology.

[15]  W. Chin,et al.  Thyroid hormone receptor monomer, homodimer, and heterodimer (with retinoid-X receptor) contact different nucleotide sequences in thyroid hormone response elements. , 1994, Endocrinology.

[16]  L. Agellon,et al.  Regulation of the human cholesterol 7alpha-hydroxylase gene (CYP7A1) by thyroid hormone in transgenic mice. , 2004, Endocrinology.

[17]  J. Oppenheimer,et al.  Functional relationship of thyroid hormone-induced lipogenesis, lipolysis, and thermogenesis in the rat. , 1991, The Journal of clinical investigation.

[18]  J. Harney,et al.  Type 2 iodothyronine deiodinase is highly expressed in human thyroid. , 1996, The Journal of clinical investigation.

[19]  Mary E. McGrath,et al.  A structural role for hormone in the thyroid hormone receptor , 1995, Nature.

[20]  P. Ladenson,et al.  Augmented hepatic and skeletal thyromimetic effects of tiratricol in comparison with levothyroxine. , 1997, The Journal of clinical endocrinology and metabolism.

[21]  J. C. Emmett,et al.  Selective thyromimetics. Cardiac-sparing thyroid hormone analogues containing 3'-arylmethyl substituents. , 1989, Journal of Medicinal Chemistry.

[22]  A. L'Abbate,et al.  Low-T3 Syndrome: A Strong Prognostic Predictor of Death in Patients With Heart Disease , 2003, Circulation.

[23]  Paul Webb,et al.  Selective modulation of thyroid hormone receptor action , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[24]  A. Burger,et al.  Differences between the effects of thyroxine and tetraiodothyroacetic acid on TSH suppression and cardiac hypertrophy. , 2001, European journal of endocrinology.

[25]  C. Harington.  Chemistry of Thyroxine: Isolation of Thyroxine from the Thyroid Gland. , 1926, The Biochemical journal.

[26]  S. Goldman,et al.  Pilot Studies on the Use of 3,5-Diiodothyropropionic Acid, a Thyroid Hormone Analog, in the Treatment of Congestive Heart Failure , 2002, Cardiology.

[27]  G. Barger,et al.  Chemistry of Thyroxine: Constitution and Synthesis of Thyroxine. , 1927, The Biochemical journal.

[28]  J. Gross,et al.  The identification of 3:5:3'-L-triiodothyronine in human plasma. , 1952, Lancet.

[29]  P. Beck‐Peccoz,et al.  Clinical and hormonal outcome after two years of triiodothyroacetic acid treatment in a child with thyroid hormone resistance. , 1997, Thyroid : official journal of the American Thyroid Association.

[30]  R Abagyan,et al.  Rational discovery of novel nuclear hormone receptor antagonists , 2000, Proc. Natl. Acad. Sci. USA.

[31]  C. Howes,et al.  Reduction of cardiovascular and thyroxine-suppressing activities of L-T3 by liver targeting with cholic acid. , 1992, Biochemical pharmacology.

[32]  S. Nagataki,et al.  [Thyroid hormone]. , 1990, Nihon rinsho. Japanese journal of clinical medicine.

[33]  R. Guy,et al.  Quantitative Proteomics of the Thyroid Hormone Receptor-Coregulator Interactions*[boxs] , 2004, Journal of Biological Chemistry.

[34]  P. Webb.  Selective activators of thyroid hormone receptors , 2004, Expert opinion on investigational drugs.

[35]  F. Santini,et al.  Thyromimetic effects of 3,5,3'-triiodothyronine sulfate in hypothyroid rats. , 1993, Endocrinology.

[36]  I. Klein,et al.  Thyroid disease and the heart. , 2007, Circulation.

[37]  I. Klein,et al.  Thyroid hormone and the cardiovascular system. , 1997, The New England journal of medicine.

[38]  L. Duntas.  Thyroid disease and lipids. , 2002, Thyroid : official journal of the American Thyroid Association.

[39]  N. Boon,et al.  Thyroid disease and the heart , 2000, Heart.

[40]  M. Weiner,et al.  Thyroid hormone improves function and Ca2+ handling in pressure overload hypertrophy. Association with increased sarcoplasmic reticulum Ca2+-ATPase and alpha-myosin heavy chain in rat hearts. , 1997, The Journal of clinical investigation.

[41]  J. Bringer,et al.  [Long term follow up of medical treatment of differentiated thyroid cancer]. , 1995, Annales d'Endocrinologie.

[42]  A. Pietrzykowski,et al.  Dynamic nongenomic actions of thyroid hormone in the developing rat brain. , 2006, Endocrinology.

[43]  R. Fletterick,et al.  Structure-based design and synthesis of a thyroid hormone receptor (TR) antagonist. , 2002, Endocrinology.

[44]  J. Baxter,et al.  Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine. , 2004, Endocrinology.

[45]  R J Fletterick,et al.  Hormone selectivity in thyroid hormone receptors. , 2001, Molecular endocrinology.

[46]  P. Yen,et al.  Physiological and molecular basis of thyroid hormone action. , 2001, Physiological reviews.

[47]  I. Klein,et al.  Thyroid hormone and blood pressure regulation , 2003, Current hypertension reports.

[48]  D. Cooper,et al.  Amiodarone and the thyroid. , 2005, The American journal of medicine.

[49]  G. Ness,et al.  Effects of L-triiodothyronine and the thyromimetic L-94901 on serum lipoprotein levels and hepatic low-density lipoprotein receptor, 3-hydroxy-3-methylglutaryl coenzyme A reductase, and apo A-I gene expression. , 1998, Biochemical pharmacology.

[50]  D. Solomon,et al.  Thyromimetic effects of 3,5-dimethyl,3'-isopropyl thyronine (DIMIT) and 3,5-diethyl,3'-isopropyl thyronine (DIET) in various tissues of the rat. , 1984, Metabolism: clinical and experimental.

[51]  J. Baxter,et al.  Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment. , 2002, Journal of medicinal chemistry.

[52]  Paul Webb,et al.  Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight , 2004, Trends in Endocrinology & Metabolism.

[53]  T. Osborne,et al.  Thyroid Hormone Regulation and Cholesterol Metabolism Are Connected through Sterol Regulatory Element-binding Protein-2 (SREBP-2)* , 2003, Journal of Biological Chemistry.

[54]  J. Silva.  The Thermogenic Effect of Thyroid Hormone and Its Clinical Implications , 2003, Annals of Internal Medicine.

[55]  G. Williams,et al.  Cloning and Characterization of Two Novel Thyroid Hormone Receptor β Isoforms , 2000, Molecular and Cellular Biology.

[56]  C. Lim,et al.  The thyroid hormone analogue SKF L-94901: nuclear occupancy and serum binding studies. , 1989, Clinical science.

[57]  C. Martius,et al.  [Effects of the thyroid hormone]. , 1952, Naunyn-Schmiedebergs Archiv fur experimentelle Pathologie und Pharmakologie.

[58]  G. Brenta,et al.  Comparative efficacy and side effects of the treatment of euthyroid goiter with levo-thyroxine or triiodothyroacetic acid. , 2003, The Journal of clinical endocrinology and metabolism.

[59]  M. Lazar,et al.  Transcriptional Repression by Nuclear Hormone Receptors , 2000, Trends in Endocrinology & Metabolism.

[60]  A. Burger,et al.  Organ-specific effects of 3,5,3'-triiodothyroacetic acid in rats. , 1997, European journal of endocrinology.

[61]  J. Ohisalo.  [Hormone resistance]. , 1991, Duodecim; laaketieteellinen aikakauskirja.

[62]  J. L. Leonard,et al.  Regulation of rat cerebrocortical and adenohypophyseal type II 5'-deiodinase by thyroxine, triiodothyronine, and reverse triiodothyronine. , 1985, Endocrinology.